Alexion Eculizumab - A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Multi-Center Study of Eculizumab for the Prevention of Delayed Graft Function After Kidney Transplantation in Adult Subjects at Increased Risk of Delayed Graft Function

Grants and Contracts Details

StatusFinished
Effective start/end date9/25/148/30/16

Funding

  • CTI Clinical Trial and Consulting Services: $27,749.00